The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis

Es, Nick, Ventresca, Matthew, Di Nisio, Marcello, Zhou, Qi, Noble, Simon ORCID: https://orcid.org/0000-0001-5425-2383, Crowther, Mark, Briel, Matthias, Garcia, David, Lyman, Gary H., Macbeth, Fergus, Griffiths, Gareth, Iorio, Alfonso, Mbuagbaw, Lawrence, Neumann, Ignacio, Brozek, Jan, Guyatt, Gordon, Streiff, Michael B., Baldeh, Tejan, Florez, Ivan D., Gurunlu Alma, Ozlem, Agnelli, Giancarlo, Ageno, Walter, Marcucci, Maura, Bozas, George, Zulian, Gilbert, Maraveyas, Anthony, Lebeau, Bernard, Lecumberri, Ramon, Sideras, Kostandinos, Loprinzi, Charles, McBane, Robert, Pelzer, Uwe, Riess, Hanno, Solh, Ziad, Perry, James, Kahale, Lara A., Bossuyt, Patrick M., Klerk, Clara, Büller, Harry R., Akl, Elie A. and Schünemann, Holger J. 2020. The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. Journal of Thrombosis and Haemostasis 18 (8) , pp. 1940-1951. 10.1111/jth.14824

Preview

PDF - Accepted Post-Print Version Download (692kB) | Preview

Abstract

Background Oncology guidelines suggest using the Khorana score to select ambulatory cancer patients receiving chemotherapy for primary venous thromboembolism (VTE) prevention, but its performance in different cancers remains uncertain. Objective To examine the performance of the Khorana score in assessing 6‐month VTE risk, and the efficacy and safety of low‐molecular‐weight heparin (LMWH) among high‐risk Khorana score patients. Methods This individual patient data meta‐analysis evaluated (ultra)‐LMWH in patients with solid cancer using data from seven randomized controlled trials. Results A total of 3293 patients from the control groups with an available Khorana score had lung (n = 1913; 58%), colorectal (n = 452; 14%), pancreatic (n = 264; 8%), gastric (n = 201; 6%), ovarian (n = 184; 56%), breast (n = 164; 5%), brain (n = 84; 3%), or bladder cancer (n = 31; 1%). The 6‐month VTE incidence was 9.8% among high‐risk Khorana score patients and 6.4% among low‐to‐intermediate‐risk patients (odds ratio [OR], 1.6; 95% confidence interval [CI], 1.1‐2.2). The dichotomous Khorana score performed differently in lung cancer patients (OR 1.1; 95% CI, 0.72‐1.7) than in the group with other cancer types (OR 3.2; 95% CI, 1.8‐5.6; Pinteraction = .002). Among high‐risk patients, LMWH decreased the risk of VTE by 64% compared with controls (OR 0.36; 95% CI, 0.22‐0.58), without increasing the risk of major bleeding (OR 1.1; 95% CI, 0.59‐2.1). Conclusion The Khorana score was unable to stratify patients with lung cancer based on their VTE risk. Among those with other cancer types, a high‐risk score was associated with a three‐fold increased risk of VTE compared with a low‐to‐intermediate risk score. Thromboprophylaxis was effective and safe in patients with a high‐risk Khorana score.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Wiley
ISSN:	1538-7933
Date of First Compliant Deposit:	24 July 2020
Date of Acceptance:	30 March 2020
Last Modified:	22 Nov 2024 07:30
URI:	https://orca.cardiff.ac.uk/id/eprint/133710

Citation Data

Cited 40 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item